The last decade of biopharmaceutial research has brought immense advancement leading to several biologics approved for the treatment of various human disease. There are about 30 approved biosimilars in the market and more are expected in the coming years. By the end of 2020, 12 biologics patents are set to expire and this trend is likely to continue in the coming years. The requirement of approval of biosimilar is that is is has to demonstrated that the biosimilar and reference compound are similar by analytical and clinical characterization methods. Bioprocessing of biosimilars could results in impurities that may have to be characterized especially for immunogenecity. Early assessment of immuonogenecity is highly desirable in understanding the complexity of downstream processing. Modern technologies allows us to determine the possible T -Cell immune response that helps in better manuovering of procees development. We can help in conducting specific immunogenicity analysis that will help you make data driven decision for your program Start Bootstrap has everything you need to get your new website up and running in no time! Choose one of our open source, free to download, and easy to use themes! No strings attached!
Company Details
- Founded
- -
- Address
- Kanagam Road, Chennai,tamil Nadu 600113,india
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.trophbio.com
- Keywords
- Biosimilar, Biologics, Biosimilar Characterization, Immunogenicity Assesment, T-Cells, Functional Assays, Activity Assays.
- HQ
- Chennai, Tamil Nadu
Troph Bio Questions
Troph Bio's website is https://www.trophbio.com
Troph Bio's LinkedIn profile is https://in.linkedin.com/company/troph-bio
Troph Bio's industry is
Biotechnology Research
Troph Bio's categories are Biotechnology Research
Troph Bio's founding year is 2017
